Five of seven clinical milestones in managing Duchenne muscular dystrophy (DMD) occurred significantly later for Black males than for…
Joana Vindeirinho, PhD
Joana is a Science Writer at BioNews. She is a cell biologist with a PhD in neurobiology of disease (University of Coimbra, Portugal), focused on the role of the adenosinergic system in the early stages of diabetic retinopathy. She moved from research into high-impact medical editing in 2017, before shifting into a more direct science writing and communication role in 2022.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Joana Vindeirinho, PhD
Regenxbio has started recruiting patients for the Phase 1/2 clinical trial to assess the safety and effectiveness of…
The U.S. Food and Drug Administration (FDA) has given fast-track designation to AOC 1020, an investigational therapy for facioscapulohumeral…
Entrada Therapeutics has selected ENTR-601-45 as an investigational therapy candidate for people with Duchenne muscular dystrophy (DMD) who…
The U.S. Food and Drug Administration (FDA) is reviewing vamorolone for Duchenne muscular dystrophy (DMD) and has set…